• Company
  • Technology
  • Team
    • Board of Directors
    • Management
    • Extended Management
    • Project Management
  • Partners & Advisors
    • Preclinical Research
    • Clinical Research
    • Strategic Investment
  • Investors
  • News
    • Company News
    • Scientific Publications
  • Contact

Company News

Impfen wir bei Covid-19 bald über die Nase?

7 August 2023

Nasal vaccine against coronavirus further improved

13 June 2023

New vaccine concept against SARS-CoV-2 successfully tested

5 June 2023

Swiss Rockets AG Welcomes Three New Key Members To The Team

18 April 2023

RocketVax Nasal Vaccine to Prevent COVID-19 Passes First Tests

4 April 2023

CNN Health Reports About RocketVax Covid-19 Nasal Vaccine

3 April 2023

RocketVax has successfully completed another round of financing; The development of the second-generation COVID-19 vaccine moves forward

6 February 2023

Volker Thiel: "Wir planen noch besseren Corona-Impfschutz"

15 November 2022

RocketVax AG Announces New Milestones in the Development of Second-Generation COVID-19 Vaccines

23 September 2022

Dr. Vladimir Cmiljanovic is a recipient of the 2023 Nikola Tesla Spirit Award

31 January 2023

Burkhard Frey joins Rocketvax AG as Chief Commercial Officer

22 August 2022

SRF: Research on nasal corona vaccines raises hopes

22 August 2022

Dr. Milan Crnogorac joins RocketVax AG as Chief Technology Officer

9 August 2022

Bilanz: Important Milestone

28 June 2022

Finanz und Wirtschaft: Doubts about the market for corona boosters

24 June 2022
contact@rocketvax.com +41 61 561 54 21

RocketVax AG

c/o Swiss Rockets AG

Rittergasse 3, 4051 Basel

Switzerland

Contact Us

Your Name*

Your Email*

Subject

Message

Privacy Policy Legal Disclaimer
© Copyright 2023. RocketVax AG. All rights reserved